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Abstract
Studies on the effect of scopolamine on memory are abundant but so far only regulation of the muscarinic receptor (M1)
has been reported. We hypothesized that levels of other cholinergic brain receptors as the nicotinic receptors and the N-
methyl-D-aspartate (NMDA) receptor, known to be involved in memory formation, would be modified by scopolamine
administration. C57BL/6J mice were used for the experiments and divided into four groups. Two groups were given
scopolamine 1 mg/kg i.p. (the first group was trained and the second group untrained) in the multiple T-maze (MTM), a
paradigm for evaluation of spatial memory. Likewise, vehicle-treated mice were trained or untrained thus serving as
controls. Hippocampal levels of M1, nicotinic receptor alpha 4 (Nic4) and 7 (Nic7) and subunit NR1containing complexes
were determined by immunoblotting on blue native gel electrophoresis. Vehicle-treated trained mice learned the task and
showed memory retrieval on day 8, while scopolamine-treatment led to significant impairment of performance in the MTM.
At the day of retrieval, hippocampal levels for M1, Nic7 and NR1 were higher in the scopolamine treated groups than in
vehicle-treated groups. The concerted action, i.e. the pattern of four brain receptor complexes regulated by the
anticholinergic compound scopolamine, is shown. Insight into probable action mechanisms of scopolamine at the brain
receptor complex level in the hippocampus is provided. Scopolamine treatment is a standard approach to test cognitive
enhancers and other psychoactive compounds in pharmacological studies and therefore knowledge on mechanisms is of
pivotal interest.
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Introduction
Scopolamine, a tropane alkaloid, is a very potent psychoactive
drug that is used as a standard/reference drug for inducing
amnesia in mammals. A characteristic feature of these alkaloids is
that subjects do not recall memories of the time they were
intoxicated, and the user loses all sense of reality. The effects are
generally interpreted as a cholinergic deficit and related to the fact
that acetylcholine is involved in memory functions.The use of
scopolamine as a pharmacological model of ‘cholinergic amnesia’
became very popular after the cholinergic hypothesis of geriatric
memory dysfunction was postulated [1]. This hypothesis assumes
that the age-related decline in cognitive functions is predominantly
related to the decrease of the integrity of cholinergic neurotrans-
mission. Since scopolamine-induced amnesia was proposed to be
due to blockade of cholinergic neurotransmission, this substance
was used to model the cognitive deficits that could be observed in
aging and dementia. Scopolamine appears to be a nonselective
muscarinic receptor antagonist and it has been demonstrated that
scopolamine has a high selectivity for the muscarinic receptor [2],
although it has been reported that high doses of scopolamine are
also blocking nicotinic receptors [3]. The scopolamine model is
used extensively for preclinical testing of new substances designed
to treat cognitive impairment [4–9].
First studies that investigated the central effects of scopolamine
in animals were reported in the fifties [10,11]. Scopolamine was
also used to test the hypothesis which stated that cholinergic
neurotransmission is acting as an inhibitor of an ‘‘activating
system’’, whereby scopolamine was used to show that a muscarinic
antagonist induced behavioral disinhibition [12]. In later studies
the effects of scopolamine were investigated in experiments that
examined the effects on cognitive functions. In a passive avoidance
test bilateral hippocampal scopolamine injections decreased the
step-through latency after post-training administration [13]. The
effects of intra-hippocampal scopolamine have also been investi-
gated in reinforced T-maze alternation and visual discrimination
[14]. In this study it was found that the visual discrimination
performance was impaired at a dose of 35 mg whereas the delayed
alternation performance was already impaired at a dose of 12 mg.
Consequently, it was argued that working memory was more
sensitive to blockade of the hippocampal cholinergic synapses than
reference memory. The hippocampal cholinergic system has also
been suggested to play a role in potentiation of odor by taste
conditioning and odor aversion learning [15]. It was revealed that
scopolamine delayed the extinction of the odor aversion
conditioning. In a T-maze task scopolamine induced a reduction
in alternation performance which was most pronounced after the
first injection [16]. Scopolamine impaired the repeated acquisition
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spatial working memory [17]. In a three-panel runway task, which
assesses working- and reference memory performance, scopol-
amine increased the number of working memory errors whereas
the reference memory performance was not affected [18]. It has
been found that daily injections with scopolamine impaired the
acquisition of an eight-arm radial maze [19]. Scopolamine
disrupted acquisition performance of all rats in this radial maze
task. Since this procedure forces rats to use spatial cues to guide
their behavior, it was tentatively concluded that scopolamine
affected spatial working memory. A further study revealed that
scopolamine increased the number of errors of trained rats in an
eight-arm radial maze without using a delay between choices [20].
The effects of scopolamine have also been investigated in the
Morris water maze (MWM) to evaluate the role of the cholinergic
system in spatial learning in rats and mice: the effects of
scopolamine were impairment of the acquisition performance in
this task [21].
A more detailed analysis of the effects of scopolamine in the
MWM examined the effects of pre-training and pre-treatment
[22–24]: Using a relative high dose of scopolamine, it was found
that pre-training prevented the scopolamine-induced spatial
learning impairment observed in naive group [22,24–26].
Scopolamine-treated C57BL/6J showed reduced learning ability
[27] in the MWM and Harrison et al. [28] observed scopolamine-
induced cognitive deficits in B6C3F1/J mice using the MWM. As
shown by observations in a radial maze, Godding et al. [29]
proposed that scopolamine side-effects (as sedation, impairment of
coordinative and reactive skills, visual disturbances) may be
responsible for the apparent decline in this spatial memory
paradigm.
It was the aim of the current study to show hippocampal
patterns of major brain receptors known to be involved in memory
processes paralleling scopolamine-induced impaired memory
retrieval.
Results
Basic neurological and physiological observational
assessment
In this neurological observational battery spatial locomotion was
decreased whereas startle response in scopolamine-treated mice
was increased. Grip strength and wire manoeuvre were reduced in
scopolamine-treated mice (table 1).
The Rota rod
In the rota rod scopolamine-treated mice showed shorter
performance on the revolving rod indicating decreased motor
coordination or strength (figure 1)
Multiple T-maze
In the MTM vehicle-treated mice learned the task expressed as
latencies in seconds, in contrast to scopolamine-treated animals
(figure 2A). Untrained mice did not learn the task but were
spending the same time in the maze without any reward.
Vehicle-treated mice showed shorter pathlength as scopol-
amine-treated mice (figure 2B). As shown in figure 2C there were
significantly more correct decisions in the vehicle-treated group.
The number of successful entries into the goal box was
unequivocally higher in vehicle-treated mice (figure 2D).
At the probe trial on day 8 vehicle-treated mice showed
significantly shorter latencies than the scopolamine-treated
animals (figure 2E).
Determination of brain receptor complexes
A single band at about 480 kDa was representing the
muscarinic receptor complex containing M1.
M1 was significantly increased in scopolamine-treated trained
mice as compared to vehicle-treated trained mice.
Scopolamine-treated and untrained animals showed higher
levels than vehicle-treated untrained animals (figure 3).
A single band was observed for nicotinic receptor alpha 7 (Nic7)
between 480 and 720 kDa.
Nic7 was significantly increased in scopolamine-treated trained
mice as compared to vehicle-treated trained mice.
Scopolamine-treated and untrained animals showed higher
levels than vehicle-treated untrained animals.
Scopolamine-treated trained mice showed increased levels as
compared to scopolamine-treated and untrained mice (figure 4).
As to the nicotinic alpha 4 receptor (Nic4) no significant
differences were observed, although a trend was observed when
scopolamine-treated and trained mice were compared to vehicle-
treated trained mice, as well as for the comparison between
scopolamine-treated untrained and vehicle-treated untrained mice
(figure 5).
NMDA receptor subunit NR1 showed two bands indicating two
different receptor complexes. The band between 480 and 720 kDa
was higher in scopolamine-treated trained mice than in vehicle-
treated trained mice.
The band at about 242 kDa was comparable between groups
(figure 6A,B).
Loading controls showed comparable protein loading as shown
in figure 7.
Correlation studies. There were no significant correlations
between parameters from the MTM and brain receptor complex
levels.
As shown in figure 8A and B there was a significant correlation
(R=20.925, P=0.008) between M1 and Nic4 receptor complex-
es and a significant correlation (R=0.902, P=0.014) between
Nic7 and NR1 (band 2).
Discussion
Blockade of muscarinic receptors by scopolamine, a muscarinic
receptor antagonist, impairs learning and memory in mice [1,30]
and inhibition of cholinergic neurotransmission by muscarinic
receptor antagonists produces profound deficits in attention and
memory.
Anagnostaras et al. examined different forms of memory in mice
with a null mutation of the gene encoding the M1 receptor, the
most densely distributed muscarinic receptor in the hippocampus
and forebrain: Long-term potentiation (LTP) in response to theta
burst stimulation in the hippocampus was reduced in mutant mice.
M1 null mutant mice showed normal or enhanced memory for
tasks that involved matching-to-sample problems, but they were
severely impaired in non-matching-to-sample working memory as
well as consolidation. Their results suggest that the M1 receptor is
specifically involved in memory processes for which the cortex and
hippocampus interact [31].
The M1 subtype is the most abundant of the muscarinic
receptors in the forebrain and hippocampus [32,33] and Park et
al. [34] provided further evidence for a key role of M1 receptors in
memory and cognition.
Acetylcholine (Ach) activates two families of receptors that
mediate its action in target tissues: nicotinic receptors, which
function as ligand-gated cation channels that participate in rapid
postsynaptic neurotransmission, and muscarinic receptors
(mAChR), members of family A G-protein coupled receptors
Scopolamine and Brain Receptor Changes
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circuits within the CNS. These two classes of receptor families
were originally named for their specific activation by nicotine and
muscarine, respectively, but have been extensively characterized
since that time on a molecular basis.The diversity and complexity
of muscarinic cholinergic signaling is facilitated in part by five
distinct receptor subtypes, M1–M5, the genes for which were
cloned in the mid to late 1980s [35–37]. These intronless genes
encode muscarinic receptor proteins that have the typical
structural features of the seven transmembrane helix GPCR
superfamily, the largest family of cell-surface receptors and key
regulators of a wide variety of physiological processes [38]. In situ
hybridization experiments following the cloning of mAChR
subtype genes revealed that individual subtypes were expressed
Table 1. Observational battery average results of all mice treated with scopolamine or vehicle.
Vehicle-treated Scopolamine-treated
mean ± SD mean ± SD T-test
Body position 3.7560.82 3.8560.00 0.724
Palpebral closure 0.0560.00 060.00 0.320
Locomotor activity 2.5560.00 2.660.00 0.808
Bizarre behavior 060.00 060.00
Exophtalmus 060.00 060.00
Respiration rate 3.7560.00 3.960.82 0.358
Tremor 060.00 0.02560.00 0.320
Twitches 060.00 060.00
Transfer arousal 3.6560.41 3.4560.55 0.132
Spatial locomotion* 3.261.03 2.46360.88 0.000
Startle response* 3.6561.26 4.4561.79 0.015
Piloerection 460.00 3.97560.00 0.320
Ataxic/Hypotonic/impaired gait 060.00 060.00
Limb rotation 3.97560.00 3.9560.00 0.562
Pelvic elevation 4.160.82 460.82 0.699
Tail elevation 2.260.00 2.3560.00 0.336
Finger approach 3.7560.00 3.960.00 0.241
Finger withdrawal 3.6560.82 3.860.00 0.452
Touch escape 3.961.79 4.261.10 0.412
Positional passivity 060.00 060.00
Visual placing 2.360.41 2.561.60 0.299
Grip strength* 4.7561.10 5.460.00 0.007
Body/Abdominal tone 5.5560.00 5.660.00 0.788
Hypothermia 060.00 060.00
Pinna reflex 2.7560.00 562.42 0.000
Cornea 3.5561.10 3.361.97 0.619
Toe pinch 5.562.34 5.161.03 0.713
Wire maneuvre* 1.7562.19 2.661.03 0.037
Skin color 460.00 460.00
Diarrhea 0.02560.00 060.00 0.320
Limb tone 460.00 460.00
Lacrimation/Salivation 060.00 060.00
Provoked biting 2.160.55 2.160.00 1.000
Vocalization 060.00 060.00
Tail pinch 2.22560.82 2.161.51 0.597
Righting reflex 160.00 160.00
Negative geotaxis 060.00 060.00
Cliff avoidance 0.9560.00 0.960.00 0.402
Vestibular drop 060.00 060.00
Proprioception 160.00 160.00
*significant.
doi:10.1371/journal.pone.0032082.t001
Scopolamine and Brain Receptor Changes
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32082in partially overlapping tissues, with some regions, including the
hippocampus, expressing all five mAChR subtypes [39,40].
Several of the muscarinic receptor subtypes M1–M5 might
underlie the cognitive effects of scopolamine. Evidence for a role
in mnemonic processes in both rodents and humans is strongest for
the postsynaptic muscarinic M1 receptor [41–46]. This receptor is
predominantly located in brain regions thought to be important
for learning and memory such as cortex and hippocampus; the
presence of the M1 receptor in the periphery is relatively limited
[47,48]. Hence, M1 antagonists are considered an interesting
option with regards to finding novel pharmacological alternatives
to induce cognitive impairment which are not so much hampered
by issues of nonselectivity or peripheral side-effect [9,41].
Nicotinic cholinergic receptors are a class of ligand-gated ion
channels that are assembled from five subunits out of at least 17
identified subunits and are differentially expressed in both the
central and peripheral nervous systems [49–52]. Neuronal
nAChRs have a pentameric structure and are comprised of either
a (a7–a10) subunits or a combination of a (a2–a6) and b (b2–b4)
subunits [53–56] In the central nervous system, the a4b2* which
includes subclasses differentiated by the inclusion of a3, a5o ra6
subtypes [56,57] and a7 nAChRs are the two predominant
nAChR subtypes [58,59], but they have diverse functional
properties [60–63].
Herein, in a paradigm of spatial memory, increased levels of a
M1 receptor complex were observed following scopolamine
treatment in both, trained and untrained mice. As M1 receptors
are colocalized with NMDA receptors in hippocampal pyramidal
neurons, and co-activation with NMDA receptors results in
amplified NMDA currents [64], we also determined a key subunit
of the NMDA receptor complex, NR1. Increased NR1 complex
levels have been shown to appear in spatial memory formation
[65] and indeed, NR1 complex levels were increased in
scopolamine-treated trained animals as compared to vehicle-
treated trained animals. A possible M1 – NR1 interaction is also
supported by the fact that the disruptive effect of scopolamine was
intensified when NMDA receptor antagonists were co-adminis-
tered at doses that had no effect on the maze performance by
themselves, while the selective AMPA antagonist YM90K failed to
affect the disruptive effect of scopolamine [66]. This proposed
interaction is further strengthened by recent data revealing that
the central cholinergic system modulates the excitatory neuro-
transmission by using excitatory amino acids as neurotransmitters
[67] and that ACh stimulation of muscarinic receptors selectively
potentiates responses to NMDA [66,68].
Muscarinic M1 receptors couple to Gq-proteins that subsequently
activate several signaling cascades via phospholipase C [47,69,70],
which in turn can influence Ca
2+ and K
+ currents [70], raise cyclic
AMP levels [69], and can stimulate other receptor systems including
NMDA receptors, i.e. currents produced by hippocampal CA1
pyramidal neurons [64,71,72]. Moreover, M1 receptors and NR1
receptor subunits were found to be colocalized at glutamatergic
synapses, suggestive of a direct interaction between another receptor
system. A link between M1 receptor signaling and long-term
potentiation (LTP), a mechanism which is thought to underly
learning and memory processes, has also been put forward [73–79].
Based upon participation in the cholinergic system and the fact
that Nic4 and Nic7 have been described to be key elements in
memory formation we decided to determine Nic4 and Nic7
receptor complex levels in order to show involvement in
scopolamine-induced memory impairment. And indeed, Nic7
was increased in scopolamine-treated trained mice as compared to
vehicle-treated trained mice and also scopolamine-treated un-
trained animals showed higher Nic7 receptor complex levels than
vehicle-treated and untrained mice.
A significant difference between scopolamine-treated trained and
untrained animals was shown, providing evidence for the notion
that sopolamine is modulating even this brain receptor subtype.
No significant correlation was observed between Nic7, M1 and
NR1 and the observed correlations between M1 and Nic4 is of no
obvious meaning in this context as Nic4 was not significantly
modified by scopolamine treatment and so is the interpretation for
the correlation between Nic7 and NR1 band 2, that was not
regulated by scopolamine either.
Figure 1. Results in the Rota rod. Significant differences in rota rod performance, in scopolamine-treated vs vehicle-treated groups (P#0.05) are
shown. Numbers are representing seconds of remaining on the revolving rod.
doi:10.1371/journal.pone.0032082.g001
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complex level with parameters from the MTM.
Taken together, we have shown the concerted action of
hippocampal M1, NR1, Nic4 and Nic7 receptor complexes. The
innovative result is that we have not only revealed the change of a
single receptor subunit but a pattern of receptor complexes and
this is of importance as the receptor complexes rather than simply
subunits are functional. Moreover, it was shown that hippocampal
levels of these four brain receptors, known to be essential for
memory formation, were modified by scopolamine, showing
scopolamine-dependent expression or levels and interplay of brain
receptors along with impairment in memory retrieval, as the probe
trial was carried out on day 8 following 4 days of learning.
Receptor complex levels of GluR1 and GluR2 [80], M1 and Nic7
[81] have been already shown to parallel memory training in
paradigms of spatial memory. In addition, it may well be that
neurological deficits shown in the neurological observational
battery and on rota rod may represent altered muscarinergic
and nicotinergic innervation and may even have been affecting
behavior and performance in the multiple T-maze.
The broad array of deficits produced by anticholinergics such as
scopolamine, atropine or more selective ligands could result from
action at multiple receptor subtypes.
Materials and Methods
Ethics statement
Experiments were done under license from the Federal Ministry
of Education, Science and Culture, which includes an ethical
evaluation of the project (Approval number: BMWF-66.009/
Figure 2. Results in the MTM. Significantly higher latencies and longer pathlengths were observed in the scopolamine-treated animals (A,B).
Correct decisions to reach the goal box were higher in vehicle-treated and trained mice (C) and the number of successful entries into the goal box
during training days was significantly higher in the vehicle-treated and trained mice (D). At the probe trial latencies were significantly lower in the
vehicle-treated and trained mice (E).
doi:10.1371/journal.pone.0032082.g002
Scopolamine and Brain Receptor Changes
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32082Figure 3. Western blot results of M1. The M1 receptor complex levels were significantly higher in scopolamine-treated groups.
doi:10.1371/journal.pone.0032082.g003
Figure 4. Western blot results of Nic 7. Nic7 complex levels were significantly higher in scopolamine-treated groups. Significant differences were
also observed when scopolamine-treated trained and untrained mice were compared.
doi:10.1371/journal.pone.0032082.g004
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compliance with European and national regulations.
Animals
C57BL/6J mice (6 per group, total n=24, male, aged 10–12
weeks) were used for the study. Mice were obtained from
JANVIER SAS laboratory (France) and maintained in cages
made of Makrolon and filled with wood chips in the core unit
of Biomedical Research, Division of Laboratory Animal
Science and Genetics, Medical University of Vienna. All mice
were bred and maintained in polycarbonate cages Type II (207
9 140 9 265 mm, Ehret, Austria) and filled with autoclaved
wood chips (Ligncell select, Rettenmaier,Austria). An auto-
claved Altromin standard rodent diet (Altromin, Germany) and
water were available ad libitum. Room temperature was
2261uC and relative humidity was 50610%. The light/dark
rhythm was 14:10.Ventilation with 100% fresh air resulted in
an air change rate of 15 times per hour. The room was
illuminated with artificial light at an intensity of about 200 l6
in 2 m from 5 a.m. to 7 p.m. The MTM was performed
between 8 a.m. and 1 p.m.
Experimental design
This study examines the C57BL/6J mouse strain which is the
most commonly used strain in behavioral studies. The advantage
of inbred strains is that they possess clearly defined genomes: for
each strain, resulting from several generations of brother x sister
mating, all the subjects have identical genes, excepting for the sex-
related genes.
Mice were treated with Scopolamine hydrochloride (Sigma-
Aldrich, St. Louis, MO), 1 mg/kg (30 min before all trials,
including the probe trial on day 8, ip) [27,28,82,83]. Four groups
(6 animals per group) were used. The first group obtained
scopolamine and was tested in the MTM with reward in the goal
box. (scopolamine-treated and trained). The second group was
scopolamine-treated in the same way but had no reward in the
goal box. (scopolamine-treated and untrained). The third group
was given a sodium chloride solution and was tested in the MTM
with reward in the goal box (vehicle-treated and trained) and the
fourth group was given a sodium chloride solution without any
reward in the goal box (untrained and untrained).
Behavioral studies
Behavioral studies as observational assessment and rota rod
were carried out 1 week prior to testing in the MTM.
Basic neurological and physiological observational
assessment (OB). The procedure was following the set up by
Irwin [84]. A battery of tests was applied to reveal defects in gait or
posture, changes in muscle tone, grip strength, visual acuity and
temperature. To complete the assessment, vitally important
reflexes were scored. Throughout the manipulations incidences
of abnormal behaviour, fear, irritability, aggression, excitability
are monitored.
Rota rod (RR). The rota rod (Rota Rod ‘‘Economex’’,
Columbus Instruments, Ohio, USA) tests balance and
coordination and comprises a rotating drum which is accelerated
from 4 to 40 rpm over the course of 5 min. The time at which
each animal falls from the drum will be recorded automatically
when it contact a plate which will stop the timer. Each animal
Figure 5. Western blot results of Nic 4. Although a trend was suggested no significant differences between groups were observed.
doi:10.1371/journal.pone.0032082.g005
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three more consecutive trials and the longest time on the drum was
used for analysis [85].
Multiple T-maze (MTM). In this spatial learning task,
animals learn to find the goal box based on their memory of
previously visited arms [80,86,87]. The MTM is constructed of
wood and consists of a wooden platform with seven choice points
and the dimensions 150 cm6130 cm615 cm and a path width of
8 cm (figure 9). Prior to testing, mice were deprived of food for
16 h to motivate food searching. Mice were placed in a start box
in a black cylindrical start chamber. Each trial started with them
leaving the start box and was completed when mice had reached
the goal box or, if failed, after 5 min. Upon arriving in the goal
box, mice were allowed to consume a small piece of a food pellet
as provided reward and transferred to their home cage.
Immediately after each trial, the entire maze was cleaned with
1% incidin solution. After testing, animals were given food as per
body weight (120 g/kg) into the home cage, representing the
amount to maintain their body weight but keep them hungry for
the following day for MTM tests. Mice were trained with 3 trials
per day for 4 days. Trials were carried out using 20 min intervals.
Trials were recorded using a computerized tracking/image
analyzer system (video camcorder: 1/3 in. SSAMHR EX
VIEWHAD coupled with computational tracking system:
TiBeSplit). The system provided the following parameters,
correct or wrong decisions (wrong means a path ending), path
Figure 6. Western blot results of NR1. NR1 containing NMDA complex levels (band 1) were significantly increased in the scopolamine-treated
trained group vs the vehicle-treated and trained panel (A). Band 2 (B) was not significantly different between groups.
doi:10.1371/journal.pone.0032082.g006
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experimental day (memory retention), subjects were undergoing a
probe trial for 5 min. Mice were allowed to explore the maze and
path length, time to reach the goal and correct and wrong
decisions were recorded.
Yoked controls were placed into the MTM to remain the same
time as their trained mates, but without food provided. Since
animals were exposed to the same spatial cues, but without food,
mice did not develop an association between the extra-maze cues
and the location of the food.
After completion of each cognitive test, mice were deeply
anaesthetized (CO2) and sacrificed by neck dislocation. Hippo-
campi were rapidly dissected and stored at 280uC for further
proteomic and biochemical analysis.
Protein studies
Sample preparation. 12 hippocampi of trained and
untrained mice each were homogenized in ice-cold
homogenization buffer [10 mM HEPES, pH 7.5, 300 mM
sucrose, one complete protease inhibitor tablet (Roche
Molecular Biochemicals, Mannheim,Germany) per 50 mL] by
Ultra-Turrax (IKA,Staufen, Germany). The homogenate was
centrifuged for 10 min at 1,0006g and the pellet was discarded.
The supernatant was centrifuged at 50,0006 g for 30 min in an
ultracentrifuge (Beckman Coulter Optima- L-90K).
Subsequently,the pellet was homogenized in 5 mL washing
buffer (homogenization buffer without sucrose), kept on ice for
30 min and centrifuged at 50,0006g for 30 min. All individual 24
samples were used for the gel experiments, using sucrose gradient
ultracentrifugation for membrane fractionation. The plasma
membrane purification procedures from the pellet were carried
out as described previously, with slight modifications [65,88,89].
Sucrose density gradient centrifugation solutions of 700 mL each of
69, 54, 45, 41, and 37% (w/v) were formed. Membrane pellets in
500 mL were resuspended in homogenization buffer, layered on
top of the tubes that were filled with homogenization buffer.
Samples were ultracentrifuged at 4uC at 70,0006g for 3 h. After
centrifugation the 41% fraction from the sucrose interface was
collected, diluted 10 times with homogenization buffer, and then
ultracentrifuged at 4uC at 100,0006g for 30 min. After discarding
the supernatant, the pellet was stored at 280uC until use.
Blue native-polyacrylamide gel electrophoresis(BN-
PAGE). Membrane pellets from the 41% sucrose gradient
Figure 7. Loading control. The membrane used for immunoblotting
was stained by Coomassie blue R-350. Adaequate loading was shown.
doi:10.1371/journal.pone.0032082.g007
Figure 8. Significant correlations. (A) The significant correlation between Nic4 and M1 complex levels as well as (B) the significant correlation
between NR1 (band 2) and Nic7 is demonstrated.
doi:10.1371/journal.pone.0032082.g008
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[1.5 M 6-aminocaproic acid, 300 mM Bis–Tris, pH 7.0] and 10%
DDM (n-dodecyl b-D-maltoside) [to achieve final 1% DDM
concentration] with vortexing every 10 min for 1 h. Following
solubilization,samples were cleared by centrifugation at 20,0006g
for 60 min at 4uC. The protein content was estimated using the
BCA protein assay kit (Pierce, Rockford, IL, USA). 50 mg of the
membrane protein preparation were applied onto gels. 16 mLB N
PAGE loading buffer [5% (w/v) Coomassie G250 in 750 mM 6-
aminocaproic acid] were mixed with 100 mL of the membrane
protein preparation and loaded onto the gel. BN-PAGE was
performed in a PROTEAN II xi Cell (BioRad, Germany) using
4% stacking and 5–18% separating gel.The BN-PAGE gel buffer
contained 500 mM 6-aminocaproic acid, 50 mM Bis-Tris,
pH 7.0; the cathode buffer 50 mM Tricine, 15 mM Bis–Tris,
0.05% (w/v) Coomassie G250, pH 7.0; and the anode buffer
50 mM Bis–Tris, pH 7.0. The voltage was set to 50 V for 1 h,
75 V for 6 h, andwas increased sequentially to 400 V (maximum
current 15 mA/gel, maximum voltage 500 V) until the dye front
reached the bottom of the gel [65,89]. Native high molecular mass
markers were obtained from Invitrogen (Carlsbad, CA, USA).
Western blots. Membrane proteins were transferred from
BN-PAGE and BN/SDS-PAGE to PVDF membranes. After
blocking of membranes for 1 h with 10% non-fat dry milk in 0.1%
TBST (100 mM Tris–HCL, 150 mM NaCl, pH 7.5, 0.1% Tween
20), membranes were incubated with diluted primary antibodies
rabbit anti-mouse Muscarinic M1 (1:3,000, Abcam, ab75178;
Cambridge, UK), rabbit anti-mouse Nicotinic Acetylcholine
Receptor alpha 4 (1:5,000, Abcam, Cambridge, ab41170, UK)
rabbit anti-mouse Nicotinic Acetylcholine Receptor alpha7
(1:25,00, Abcam, Cambridge, ab 23832, UK), rabbit anti-mouse
NMDAR1(1:5,000, Abcam,Cambridge, ab 28669, UK) and
detected with horseradish peroxidase-conjugated anti-rabbit IgG
(Abcam, Cambridge,UK). Membranes were developed with
the ECL Plus Western Blotting Detection System (GE
Healthcare,Buckinghamshire, UK). Arbitrary optical densities of
immunoreactive bands were measured by the Image J software
program (http://rsb.info.nih.gov/ij/) [80]. Loading controls were
carried out by staining membranes by Coomassie blue as given in
a previous publication [90].
Statistical calculations
Results from the MTM were analyzed by ANOVA. The level of
probability was considered significant at P#0.05. Data from
Western blotting were handled by unpaired Student’s t test and
data are given as means 6 SD. Pearson correlations were
calculated for relations between receptor systems. Calculations
were performed using SPSS for windows 15.0 [80].
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